Memorial Sloan-Kettering Cancer Center (MSKCC) is a free-standing institution founded as the New York Cancer Hospital in 1884 and now located in the upper east side of New York City, adjacent to the health sciences campuses of Cornell University Medical College and Rockefeller University. The Center's mission is the progressive control and cure of cancer through programs of research, patient care, and education. MSKCC is dedicated to the study of cancer through a defined spectrum of laboratory research, an interactive program spanning basic and clinical science, a strong capability for basic-to-clinic technology transfer, a structured program of clinical cancer research, state-of-the art clinical programs, including in-patient and out-patient clinical care, community care focused on early diagnosis and specific cancers and a strategically selected set of priorities in population-based research that addresses issues of both local and national importance. The research activities of MSKCC are administratively organized in seven research programs: Molecular Biology, Cell Biology, Cellular Biochemistry and Biophysics, Immunology, Molecular Pharmacology and Therapeutics, Clinical Research and Cancer Prevention and Control. These Programs are supported by 13 CCSG-supported Core Facilities as well as others supported entirely by institutional resources. The Core Facilities for which CCSG support is requested are: General Animal, Animal Health, Transgenic Mouse, Glassware Washing, Media Preparation, Flow Cytometry, Microchemistry, Molecular Cytology, Analytical Pharmacology, Human Tissue Procurement, Research Pharmacy Support, Biostatistics, and Clinical Research Support. Funds are also requested for Clinical Protocol Scientific Review and Monitoring and for Development.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA008748-34S2
Application #
6149522
Study Section
Subcommittee G - Education (NCI)
Program Officer
Shafik, Hasnaa
Project Start
1977-01-01
Project End
2002-12-31
Budget Start
1999-02-10
Budget End
1999-12-31
Support Year
34
Fiscal Year
1999
Total Cost
Indirect Cost
Name
Sloan-Kettering Institute for Cancer Research
Department
Type
DUNS #
064931884
City
New York
State
NY
Country
United States
Zip Code
10065
Kavaler, Joshua; Duan, Hong; Aradhya, Rajaguru et al. (2018) miRNA suppression of a Notch repressor directs non-neuronal fate in Drosophila mechanosensory organs. J Cell Biol 217:571-583
Bosse, Tjalling; Nout, Remi A; McAlpine, Jessica N et al. (2018) Molecular Classification of Grade 3 Endometrioid Endometrial Cancers Identifies Distinct Prognostic Subgroups. Am J Surg Pathol 42:561-568
Hellmann, Matthew D; Nathanson, Tavi; Rizvi, Hira et al. (2018) Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer. Cancer Cell 33:843-852.e4
Scordo, Michael; Morjaria, Sejal M; Littmann, Eric R et al. (2018) Distinctive Infectious Complications in Patients with Central Nervous System Lymphoma Undergoing Thiotepa, Busulfan, and Cyclophosphamide-conditioned Autologous Stem Cell Transplantation. Biol Blood Marrow Transplant 24:1914-1919
Byron, Sara A; Tran, Nhan L; Halperin, Rebecca F et al. (2018) Prospective Feasibility Trial for Genomics-Informed Treatment in Recurrent and Progressive Glioblastoma. Clin Cancer Res 24:295-305
Zarnegar, Sara; Durham, Benjamin H; Khattar, Pallavi et al. (2018) Novel activating BRAF fusion identifies a recurrent alternative mechanism for ERK activation in pediatric Langerhans cell histiocytosis. Pediatr Blood Cancer 65:
Francis, Jasmine H; Slakter, Jason S; Abramson, David H et al. (2018) Treatment of juxtapapillary hemangioblastoma by intra-arterial (ophthalmic artery) chemotherapy with bevacizumab. Am J Ophthalmol Case Rep 11:49-51
Lee, Stanley Chun-Wei; North, Khrystyna; Kim, Eunhee et al. (2018) Synthetic Lethal and Convergent Biological Effects of Cancer-Associated Spliceosomal Gene Mutations. Cancer Cell 34:225-241.e8
Motzer, Robert J; Escudier, Bernard; Powles, Thomas et al. (2018) Long-term follow-up of overall survival for cabozantinib versus everolimus in advanced renal cell carcinoma. Br J Cancer 118:1176-1178
Giancipoli, Romina Grazia; Monti, Serena; Basturk, Olca et al. (2018) Complete metabolic response to therapy of hepatic epithelioid hemangioendothelioma evaluated with 18F-fluorodeoxyglucose positron emission tomography/contrast-enhanced computed tomography: A CARE case report. Medicine (Baltimore) 97:e12795

Showing the most recent 10 out of 8799 publications